Skip to content

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. We aim to create a future worth living for chronically and critically ill patients – worldwide and every day.

Major events

Realignment of the operating model expands production as part of the FME25 program.

In the future, the simplified structure will comprise only two global segments: in the Care Enablement segment, Fresenius Medical Care consolidates its pre­viously decentralized product business under one global medical technology umbrella. The global health care services business will be combined in the Care Delivery segment. In this way, the company aims to become more agile, make better use of existing know-how, accelerate innovations, and deploy its capital in a more targeted and thus more efficient manner. With the implementation of the new global operating model, Fresenius Medical Care expects to reduce its annual costs by € 500 million by 2025.

Fresenius Medical Care trains patients with virtual reality technology for home dialysis.

The VR training helps patients learn how to use the stay-safe system for Continuous Ambulatory Peritoneal DialysisDialysisForm of renal replacement therapy where a semipermeable membrane – in peritoneal dialysis the peritoneum of the patient, in hemo­ dialysis the membrane of the dialyzer – is used to clean a patient’s blood. correctly. It appeals to several senses and makes it particularly easy to learn new procedures and consolidate conventional training. Patients can adjust the learning pace individually and repeat the learning units as often as necessary until they are confident in their use.

Fresenius Medical Care improves clinical care performance through continuous digital quality improvement.

Following the introduction of the Medical Patient Review Continuous Quality Improvement (MPR-CQI) program in 20 countries in the EMEA region, an improvement in medical performance indicators was observed, which was associated with a significant reduction in mortality risk of about 30%. This was confirmed by a study. For the development of the MPR-CQI program, the company used therapy data from more than 70,000 patients from its own NephroCare network.

Comprehensive dialysisDialysisForm of renal replacement therapy where a semipermeable membrane – in peritoneal dialysis the peritoneum of the patient, in hemo­ dialysis the membrane of the dialyzer – is used to clean a patient’s blood. products and services

When the kidney function of patients fails, dialysis takes over the vital task of cleansing the blood of toxins and surplus water. We offer products and services along the entire dialysis value chain. In addition to dialysis machines, dialyzers, and related disposables, we operate our own dialysis clinics worldwide. As part of our strategy 2025, we will concentrate on three key areas in which we want to leverage our core competencies – innovation of products, operating outpatient facilities, standardizing medical procedures, and efficiently coordinating patients:

Renal care continuum

By applying digital technologies such as artificial intelligence, we work on new forms of renal therapy to foster personalized medicine and holistic home care, among other things. Our value-based care models will push forward the transition from fee-for-service to pay-for-performance models to offer even better and affordable care. We are expanding these models to the treatment of chronic kidney disease and plan to include kidney transplant patients as well.

Critical care solutions

In addition to acute dialysis, we will therefore increasingly rely on our expertise in intensive care. In this area, we can draw in particular on our experience in extracorporeal blood treatment and cardiopulmonary support in acute kidney failure.

Complementary assets

To create an additional basis for future growth, we are further expanding our network of complementary assets through partnerships, investments, and acquisitions. This will help us to create additional medical value while cutting costs.

Our success factors

  • Sustainable business based on high-quality products and services
  • Strong global footprint
  • Leading market positions
  • Highly qualified employees
  • High level of vertical integration

Our growth drivers

  • Aging population and increasing number of patients with chronic diseases
  • Increasing presence in emerging markets
  • Standardizing medical procedures
  • Increasing demand for home hemo­dialysis
  • Providing integrated solutions for patients and health care systems
  • Developing and enhancing value-based care

Market dynamics

Increase in worldwide demand

~ 1.6 million

patients worldwide,

who will need continuous renal replacement therapy to treat acute kidney failure in 2030

Quality in dialysis treatments enables saving in the U.S. market

US$ 4.9 bn

savings

created by all dialysis providers for Medicare and taxpayers since QIP (quality incentive program) was enacted

Home dialysis

By 2025, the Company aims to perform

25 %

of all treatments in the U.S. in a home setting

Big Data is driving new treatment models

~ 53 million

dialysis treatments in 2021

providing sound data basis to further standardize medical setups at Fresenius Medical Care

Global market for dialysis products and services

~ € 79 bn

SALES BY REGION

sales by services and products

Sales and Earnings development

in € millions 2021 2020 Change Change in constant currency
Sales 12,088 12,478 -3% 0%
EBIT 1,673 2,120 -21% -18%
Employees 66,232 67,028 -1%

Asia-Pacific and Latin America

Download(XLS, 35 KB)
in € millions 2020 2019 Change Change in constant currency
Sales 2,713 2,578 5% 9%
EBIT 362 382 -5% -4%
Employees 34,036 35,916 -5%
in € millions 2021 2020 Change Change in constant currency
Sales 2,765 2,763 0% 1%
EBIT 322 412 -22% -21%
Employees 29,983 30,185 -1%

Sources:
~ 1.6 million patients require renal replacement therapy by 2030
Source: own research Fresenius Medical Care

Home dialysis
By 2025, the Company aims to perform 25 % of all treatments in the U.S. in a home setting
Source: own research Fresenius Medical Care

Global market for dialysis products and services ~ € 79 bn
Source: own research Fresenius Medical Care

Big Data is driving new treatment models ~ 53 m dialysis treatments in 2021
Source: own research Fresenius Medical Care

Quality in dialysis treatments enables saving in the U.S. market
Source: Kidney Care Partners: United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.